Close Menu

Fluxion Biosciences Spotlight Liquid Biopsy NGS Panels

Dec 12, 2019

Fluxion Biosciences has launched three new targeted next-generation sequencing liquid biopsy panels, including Spotlight Myeloid, Spotlight EGFR, and the Spotlight TP53. The Alameda, California-based firm's Spotlight Myeloid panel includes 478 amplicons that cover 23 clinically relevant genes implicated in acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. The Spotlight EGFR panel offers contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS mutations, using a 17-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. The Spotlight TP53 panel uses 21 amplicons with an average size of 140 base pairs, providing coverage of all TP53 coding regions. According to Flux Bio, the panels have been validated and come with its ERASE-Seq variant caller

More Like This

Sep 24, 2020

LabCorp: Resolution ctDx Lung Assay

LabCorp has launched the Resolution ctDx Lung assay for patients with non-small cell lung cancer (NSCLC). The test will be run by Resolution Biosciences and detects actionable mutations associated with the disease in a standard blood sample. The firm said the test can provide valuable information to help select the most effective targeted treatments for individual patients. In addition, LabCorp noted that the test is covered by Medicare. 

Sep 23, 2020

CRISPR QC and Cardea Bio CRISPR-BIND

CRISPR quality control testing firm CRISPR QC and Cardea Bio have launched CRISPR-BIND, a rapid and highly sensitive tool to characterize guide RNA and CRISPR-Cas interactions. CRISPR-BIND is the first product in a suite of quality control capabilities, the companies said. It's built on Cardea's biology-gated transistors and an automated, high throughput liquid handler to generate highly sensitive electronic signals that allow for rapid assessments of gRNA-Cas interactions directly at the bench. This includes, but is not limited to, monitoring the interactions and stability of a variety of modified gRNAs with engineered Cas enzymes.

CRISPR QC will commercialize CRISPR-BIND in the US in partnership with COBO Technologies, which will offer the product in Europe, the firms said. CRISPR QC is Cardea's first commercial partner and CRISPR-BIND is the first of a series of CRISPR QC applications that they expect to come out of the partnership.

Sep 23, 2020

Congenica COVID-19 Module

Congenica has added a COVID-19 module to its genomic analysis platform. The company said that the new add-on will support research into relationships between a patient's genome and COVID-19 infection risk, severity, and clinical outcomes. The module also helps researchers prioritize variants in curated genes based on Human Phenotype Ontology terms that suggest COVID-19 symptoms.  

Sep 23, 2020

Exagen Avise Vasculitis AAV

Exagen launched the Avise Vasculitis AAV test panel of individual analytes to assess and monitor anti-neutrophil cytoplasmic antibody-associated vasculitis. ANCA-associated vasculitis is characterized by vascular inflammation and damage, and early symptoms of the disease vary widely. Exagen's test is intended for use in patients suspected of small vessel diseases, such as granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. 

Sep 22, 2020

Bio-Techne RNA-Protein Co-Detection Assays

Bio-Techne has expanded its Advanced Cell Diagnostics-branded RNAscope technology with the release of RNA-Protein Co-Detection Assays. RNAscope technology is an advanced in situ hybridization assay that enables visualization of single-molecule gene expression with single-cell resolution directly in intact cells and tissues. The co-detection assays allow researchers to simultaneously examine gene expression specific to cell types and identify cellular sources of secreted proteins. The new workflow enables a wider range of IHC-validated antibodies to be combined with RNA ISH.

Sep 18, 2020

Bio-Rad Laboratories StarBright Violet 515 Dye for Flow Cytometry

Bio-Rad Laboratories has launched the StarBright Violet 515 (SBV515) dye, the first of a new range of fluorescent nanoparticles for flow cytometry. SBV515 has an excitation maximum at 401 nanometers and emission maximum of 516 nanometers, offering improved brightness to better resolve rare and low antigen density populations. It has a narrow emission profile to reduce spillover into neighboring filters and minimize excitation by other lasers, making it suitable for inclusion in multicolor panels. The dye is not susceptible to photobleaching, delivers high lot-to-lot reproducibility, and is stable at 4° C with no loss of signal, Bio-Rad said.

Sep 18, 2020

Akoya Biosciences Proxima Spatial Biology Platform

Akoya Biosciences this week launched the Proxima Spatial Biology Platform to integrate rapid image acquisition and secure data sharing in the cloud. The new software is designed to allow users to visualize and analyze whole-slide, multiplexed immunofluorescence images generated by Akoya's Phenoptics platform, and will soon be expanded to visualize and analyze ultra-high-plex images generated by Akoya's CODEX platform, enabling an integrated, flexible, and scalable solution from discovery to translational and clinical research, the company said.

Sep 18, 2020

RenalytixAI: KidneyIntelX

RenalytixAI has announced the commercial launch of its KidneyIntelX clinical testing platform, which provides risk assessment of progressive decline in kidney function or kidney failure in patients with early-stage diabetic kidney disease. KidneyIntelX applies machine-learning algorithms to assess predictive blood-based biomarkers and electronic health record data to identify progressive kidney disease in at-risk patients. 

The firm submitted a 510(k) application to the US Food and Drug Administration for the assay last month. 

Sep 17, 2020

Sanford Burnham Prebys Coronascape Bioinformatics Platform

Sanford Burnham Prebys Medical Discovery Institute has introduced Coronascape, a specialized version of its Metascape bioinformatics platform designed for big-data analysis of SARS-CoV-2 and COVID-19 research. The La Jolla, California-based research institute said that Coronascape is meant to serve as a multiomics data clearinghouse for efforts to develop effective targets and therapies for the novel coronavirus. SBP developed the web-based Metascape portal in partnership with the Genomics Institute of the Novartis Research Foundation and the University of California, San Diego.

Sep 15, 2020

10x Genomics Chromium Single-Cell Multiome ATAC + Gene Expression

10x Genomics has launched its Chromium Single-Cell Multiome ATAC + Gene Expression solution.

Combining the assay for transposase-accessible chromatin using sequencing with gene expression profiling by RNA sequencing, the new product enables researchers to analyze both epigenetic programming and the transcriptome in the same cell.

Sep 15, 2020

Paradigm4 Reveal: Single Cell

Paradigm4 has introduced Reveal: Single Cell, an app to help biopharmaceutical companies manage and analyze large sets of single-cell data. Reveal: Single Cell, built on top of the bioinformatics firm's SciDB database management platform, supports multiomic analysis and association. Paradigm4 said that users can choose cells across multiple studies to evaluate tissue distribution, look for variance in response to treatment, and compare normal to diseased cells. The new app is an extension of Reveal, a translational informatics platform released in 2018.

Sep 14, 2020

Bianano Genomics Lineagen EpiPanel Dx Plus

Bionano Genomics' recent acquisition Lineagen has launched the EpiPanel Dx Plus, a laboratory-developed test for epilepsy-related conditions.

The proprietary gene panel is based on 223 genes selected from a literature review, including genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen. The test is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures and can predict the recurrence risk for other members of the family and allows for personalized treatment. It has an expected diagnostic yield of 30 percent.

Sep 10, 2020

NimaGen SARS-CoV-2 WGS Kit

NimaGen of Nijmegen, the Netherlands, has launched the EasySeq SARS-CoV-2 Whole Genome Sequencing Kit. It is based on a patented reverse complement PCR (RC-PCR) library preparation method that combines target amplification and indexing into a single closed-tube PCR step, reducing hands-on time and risk of cross contamination or sample mix up. The kit includes tiled RC-PCR primer and probe pools to cover 99 percent of the viral genome with more than 90 percent read uniformity. Also included are the RC-PCR mastermix, UDI indexes, and an AmpliClean Magnetic Bead Clean-up kit.

Sep 09, 2020

CRG COVID-19 Viral Beacon Platform

The Center for Genomic Regulation (CRG) in Barcelona has launched COVID-19 Viral Beacon, a platform that lets scientists analyze raw and consensus COVID-19 genomic data from the European Nucleotide Archive (ENA), Oxford Nanopore Technologies, Illumina, NCBI/SRA, and GISAID. Users can search for specific genetic variants and explore associated metadata.

Sep 04, 2020

Combinati Q SARS-CoV-2 Triple Assay for Absolute Q Digital PCR System

Combinati has launched the Q SARS-CoV-2 Triplex Assay for its Absolute Q digital PCR system. The multiplexed, research-use-only assay detects SARS-CoV-2 nucleic acids from extracted samples in a single reaction. The workflow includes microfluidic array partitioning plates and required reagents, has one hands-on step, and provides results in 90 minutes. The assay demonstrates sensitivity down to single viral targets, enabling researchers to detect trace amounts of virus even in a high background of human genomic DNA, according to the company.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.